
|Videos|July 17, 2020
Glaucoma 360: Drug delivery contact lens technology
Author(s)Alex Delaney-Gesing
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Advertisement
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface diseases, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Development of maculopathy associated with systemic medications
3
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
4
Proactive strategies and sustained delivery advance glaucoma care
5

















































.png)


